Monitoring immune cells after CAR-T therapy for myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma (a type of blood cancer).
- You are scheduled to receive CAR-T cell therapy following standard French guidelines.
- You do not have any serious health issues that could affect your ability to follow the study plan.
- You are not currently in another clinical trial that requires a waiting period.
- You are not pregnant, breastfeeding, or under legal protection (like guardianship).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining CAR-T cell therapy with a stem cell transplant can help treat multiple myeloma. It is for patients who have already had chemotherapy but still have some signs of disease or high-risk factors.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests two new CAR-T cell therapies (LCAR-M61S and LCAR-M61D) for people whose multiple myeloma has come back or stopped responding to at least three prior treatments. The treatment uses your own immune cells that are modified to find and attack cancer cells.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.